Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

Delayed Quote. Delayed  - 10/24 10:00:40 pm
40.41 USD   -0.22%
10/21 GLOBAL BLOOD TE : Abbott Laboratories, Ortho Clinical Diagnostics, B..
10/20 ABBOTT LABORATO : People's Republic of China Clears Abbott Acquisiti..
10/20 ABBOTT LABORATO : Jones Collombin Investment Counsel Inc Lowers stak..
News SummaryMost relevantAll newsSector news 

FDA Backs Approval of Abbott's Humira for New Use

share with twitter share with LinkedIn share with facebook
share via e-mail
08/28/2012 | 10:06pm CEST

WASHINGTON--A federal advisory panel backed the use of an Abbott Laboratories (>> Abbott Laboratories) drug, Humira, as a treatment for patients with inflammatory bowel disease, saying many patients would benefit from treatment with the product.

Abbott is seeking expanded approval from the U.S. Food and Drug Administration for its anti-inflammatory drug Humira to treat ulcerative colitis. Humira, which had almost $8 billion in annual sales last year, currently is approved to treat rheumatoid arthritis, Crohn's Disease and other inflammatory conditions.

The drug was reviewed Tuesday by the FDA's gastrointestinal drugs advisory committee, which is made up of non-FDA medical experts. The panel voted 15 to 2 on a question that asked whether "the expected benefits outweigh the known and potential risks of Humira" for the treatment of certain patients with ulcerative colitis.

The vote amounts to a recommendation that the FDA approve the product. The FDA usually follows the advice of its panels but is not required to. The FDA declined to approve Humira for colitis last year and asked the company for additional information. The agency also said it would seek the advice of an advisory panel.

Abbott studied Humira in two clinical trials involving more than 1,000 patients. Both studies met goals showing Humira improved rates of disease remission compared to a placebo in people with colitis, an inflammatory bowel disease that causes pain, diarrhea and other symptoms. Patients in the studies also were being treated with older commonly used drugs for colitis including steroids.

Although the FDA agreed that the studies met their goals, the agency questioned whether the difference in remission rates of less than 10% between the Humira groups and placebo groups was "clinically meaningful." The studies showed about 17% to 19% of patients being treated with Humira achieved disease remission at eight weeks compared to about 9% of patients being treated with a placebo, according to the FDA. After one year of treatment the results were similar.

"The central issue is whether the applicant has adequately demonstrated and provided evidence of benefit sufficient to conclude that the benefit outweighs the risks of Humira for [ulcerative colitis]," the FDA said in a background memo prepared for the advisory committee meeting.

However, the majority of the panel disagreed, voting 15 to 1 saying that the differences between the drug and placebo groups were clinically meaningful.

Abbott officials and doctors who spoke on behalf of the company during the panel meeting said many patients with colitis don't respond well to currently available treatments, which also include Johnson & Johnson's (>> Johnson & Johnson) Remicade, and need an additional option. The company proposed stopping treatment in patients who don't respond to the drug after eight weeks of treatment.

Write to Jennifer Corbett Dooren at jennifer.corbett@dowjones.com

(CORRECTION: This item was corrected to show that the vote tally was 15 to 2. The original incorrectly stated 12 to 2 in the third paragraph.)

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Abbott Laboratories, Johnson & Johnson
share with twitter share with LinkedIn share with facebook
share via e-mail
10/24 ABBOTT LABORATORIES : Other Events (form 8-K)
10/21 GLOBAL BLOOD TESTING MARKET 2016 : Abbott Laboratories, Ortho Clinical Diagnosti..
10/21 DGAP-NEWS : Abbott Laboratories: Statement re Delisting From Exchange
10/20 ABBOTT LABORATORIES : An Application for the Trademark "SIMILAC NEWBORN" Has Bee..
10/20 ABBOTT LABORATORIES : An Application for the Trademark "HI-TORQUE VERSACORE" Has..
10/20 ABBOTT LABORATORIES : An Application for the Trademark "TRUSTED BY PLAYERS. PROV..
10/20 ABBOTT LABORATORIES : People's Republic of China Clears Abbott Acquisition of Al..
10/20 ABBOTT LABORATORIES : Jones Collombin Investment Counsel Inc Lowers stake in Abb..
10/20 ABBOTT LABORATORIES : Gemmer Asset Management buys $153,941 stake in Abbott Labo..
10/20 Terumo to buy U.S. vascular closure device businesses for $1.1 billion
More news
Sector news : Pharmaceuticals - NEC
03:25aDJMERCK : Drug Gets FDA Approval as a First-Line Lung Cancer Treatment
02:36aDJMERCK : Drug Gets FDA Approval as a First-Line Lung Cancer Treatment
10/24DJGLAXOSMITHKLINE : 3Q 2016 -- Forecast
10/24DJSyngenta and ChemChina Miss EU Deadline for Antitrust Remedies
10/24 GSK files potential $1 billion shingles vaccine for U.S. approval
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10/21 60% Return From Reynolds' Smoking Hot Opportunity
10/21 Alere shareholders back Abbott deal
10/20 SetPoint Leads The Crohn's Medtech Race By Being The Only Entrant
10/20 Don't Worry, It's About To Get Worse
10/19 Secret M&A Target List Leaked
Financials ($)
Sales 2016 20 941 M
EBIT 2016 3 963 M
Net income 2016 1 566 M
Debt 2016 3 122 M
Yield 2016 2,56%
P/E ratio 2016 25,49
P/E ratio 2017 17,98
EV / Sales 2016 2,99x
EV / Sales 2017 2,87x
Capitalization 59 535 M
More Financials
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 47,5 $
Spread / Average Target 17%
Consensus details
EPS Revisions
More Estimates Revisions
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Senior VP-Finance
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
Samuel C. Scott Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON10.44%310 358
ROCHE HOLDING LTD.-15.88%202 361
NOVARTIS AG-13.71%198 298
PFIZER INC.-0.31%195 193
MERCK & CO., INC.15.87%169 231
More Results